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A B S T R A C T
Background
Crohn's disease (CD) is a chronic inflammatory disorder of the gastrointestinal tract, in which the pathogenesis is believed to be partly
influenced by the gut microbiome. Probiotics can be used to manipulate the microbiome and have therefore been considered as a potential
therapy for CD. There is some evidence that probiotics benefit other gastrointestinal conditions, such as irritable bowel syndrome and
ulcerative colitis, but their eGicacy in CD is unclear. This is the first update of a Cochrane Review previously published in 2008.
Objectives
To assess the eGicacy and safety of probiotics for the induction of remission in CD.
Search methods
The following electronic databases were searched: MEDLINE (from inception to 6 July 2020), Embase (from inception to 6 July 2020),
the Cochrane Central Register of Controlled Trials (CENTRAL), The Cochrane IBD Review Group Specialised Trials Register, World Health
Organization (WHO) International Clinical Trials Registry, and ClinicalTrials.gov.
Selection criteria
Randomised controlled trials (RCTs) that compared probiotics with placebo or any other non-probiotic intervention for the induction of
remission in CD were eligible for inclusion.
Data collection and analysis
Two review authors independently extracted data and assessed the methodological quality of included studies. The primary outcome was
clinical remission. Risk ratios (RRs) and 95% confidence intervals (CIs) were calculated for dichotomous outcomes.
Main results
There were two studies that met criteria for inclusion. One study from Germany had 11 adult participants with mild-to-moderate CD,
who were treated with a one-week course of corticosteroids and antibiotics (ciprofloxacin 500 mg twice daily and metronidazole 250 mg
three times a day), followed by randomised assignment to Lactobacillus rhamnosus strain GG (two billion colony-forming units per day)
or corn starch placebo. The other study from the United Kingdom (UK) had 35 adult participants with active CD (CDAI score of 150 to 450)
randomised to receive a synbiotic treatment (comprised of freeze-dried Bifidobacterium longum and a commercial product) or placebo.
The overall risk of bias was low in one study, whereas the other study had unclear risk of bias in relation to random sequence generation,
allocation concealment, and blinding. There was no evidence of a diGerence between the use of probiotics and placebo for the induction
of remission in CD (RR 1.06; 95% CI 0.65 to 1.71; 2 studies, 46 participants) aNer six months. There was no diGerence in adverse events
Probiotics for induction of remission in Crohn's disease (Review)









Cochrane Database of Systematic Reviews
between probiotics and placebo (RR 2.55; 95% CI 0.11 to 58.60; 2 studies, 46 participants). The evidence for both outcomes was of very low
certainty due to risk of bias and imprecision.
Authors' conclusions
The available evidence is very uncertain about the eGicacy or safety of probiotics, when compared with placebo, for induction of remission
in Crohn's disease. There is a lack of well-designed RCTs in this area and further research is needed.
P L A I N   L A N G U A G E   S U M M A R Y
Probiotics for the treatment of active Crohn's disease
What is the aim of this review?
The aim of this Cochrane Review was to find out whether probiotics can induce remission in people with Crohn's disease. We analysed
information from two studies to answer this question.
Key messages
It is unclear whether probiotics are better than placebo (dummy pill). No serious adverse events occurred in either study.
What was studied in the review?
Crohn's disease is a medical condition that causes inflammation of the bowels and can lead to symptoms of ulcers in the mouth, abdominal
pain, diarrhoea, obstruction, fistulisation (tunnels between the bowels and nearby organs), abscesses, malnutrition, low haemoglobin
(blood) levels, and fatigue. There is some evidence to suggest that an imbalance in the bacteria of the gut is a cause of the disease.
Probiotics, which are live microorganisms, could alter the bacteria of the gut and possibly reduce inflammation.
What are the main results of the review?
We searched for randomised controlled trials (RCTs; clinical studies where people are randomly placed into one of two or more treatment
groups) comparing probiotics with placebo. There were two RCTs, with information on 46 people. The trials looked at adults. It is unclear
whether probiotics are diGerent to placebo for inducing remission of Crohn's disease. It is unclear whether probiotics lead to a diGerence
in adverse events (minor and serious) when compared with placebo.
Conclusion
This review found two studies that examined and showed no benefit of probiotics for the treatment of active Crohn's disease. Since the
studies were very small, no definite conclusions can be made at this time. Probiotics were generally well tolerated; there was just one side
eGect leading to the stopping of treatment with probiotics, but details of this were not given. With the evidence presented in these studies,
we are unable to make conclusions as to the eGectiveness of probiotics. Better designed studies, with more participants, are needed.
How up-to-date is this review?
This review is up-to-date as of 6 July 2020.
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S U M M A R Y   O F   F I N D I N G S
 
Summary of findings 1.   Probiotics compared to placebo for induction of remission in Crohn's disease
Probiotics compared to placebo for induction of remission in Crohn's disease
Patient or population: induction of remission in Crohn's disease
Setting: medical centers in Germany and UK
Intervention: probiotics
Comparison: placebo
Anticipated absolute effects* (95% CI)Outcomes











Study populationInduction of remission









Study populationAdverse events leading
to withdrawal









*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and
its 95% CI).
CI: confidence interval; RR: risk ratio
GRADE Working Group grades of evidence
High certainty: We are very confident that the true effect lies close to that of the estimate of the effect
Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different
Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect
Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect
1 Downgraded one level due to unclear risk of bias
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B A C K G R O U N D
Description of the condition
Crohn's disease (CD) is a chronic relapsing, remitting inflammatory
condition that can aGect any segment along the gastrointestinal
tract from the mouth to the anus. Symptoms of CD may include
oral ulcers, abdominal pain, diarrhoea, obstruction, fistulisation
to surrounding tissues, abscesses, malnutrition, and anaemia. The
diagnosis and monitoring of CD is predominantly performed via
endoscopic and histologic examination, although these can be
complemented by use of imaging, serologic, and fecal data. There
is no known cure for CD and treatment is largely focused on
the induction and maintenance of remission (quiescent disease),
correcting malnutrition, addressing complications, and improving
the quality of life for patients. In children, a major additional goal
is to facilitate normal growth and pubertal development, which
are frequently impeded. The incidence of CD is approximately 20
per 100,000 person-years in North America and 13 per 100,000
person-years in Europe (Molodecky 2012). There has been a
progressive increase in incidence and prevalence throughout
the world, particularly in regions where CD was historically not
common (e.g. Asia, the Middle East, South America). Although
the aetiology of CD is still unknown, its pathogenesis is believed
to involve the interaction between genetic and environmental
factors. In particular, the gut microbiome may play a role in disease
pathogenesis and activity, thus prompting great interest in the
potential use of probiotics as a therapeutic strategy via microbiome
manipulation (Shouval 2017).
Description of the intervention
Probiotics consist of live microorganisms that, by definition, should
benefit health in humans. Common microorganisms that have been
used as probiotics include Lactobacillus spp, Bifidobacterium spp,
Streptococcus salivarius, Escherichia coli Nissle 1917, and yeasts
(e.g. Saccharomyces boulardii) (Sartor 2005). There has been an
increasing interest in the use of probiotics for gastrointestinal
diseases, as they are considered safe and easily accessible.
How the intervention might work
Given the association between dysbiosis and CD, there is a
hypothesised role for probiotics in restoring eubiosis and perhaps
improving intestinal inflammation. Probiotics are believed to
work through competitive action with commensal and pathogenic
flora and by influencing the immune response (Shanahan 2000).
Lactobacillus, one of the more popular constituents of probiotics, is
thought to secrete bacteriocin and block the adherence of harmful
bacteria (Corr 2007; Mukherjee 2015). As such, probiotics have
been examined in diseases related to gut barrier dysfunction and
immune-mediated manifestations, such as childhood diarrhoea
(Pochapin 2000; Lai 2019), atopic dermatitis (Isolauri 2000;
Navarro-López 2018), and eczema (Schmidt 2019). There is
additionally limited evidence of eGicacy of probiotics in ulcerative
colitis (Kaur 2020; Iheozor-Ejiofor 2020), pouchitis (Nguyen 2019),
and CD (Guslandi 2000; Campieri 2000).
Why it is important to do this review
The primary mode of treatment for CD involves the use
of immunosuppressants, including immunomodulators (e.g.
azathioprine, 6-mercaptopurine, methotrexate) and biologic
therapies (e.g. infliximab, vedolizumab, ustekinumab). These
drugs are not always eGective (Colombel 2010; Limketkai
2017) and may expose patients to potentially increased risks,
such as infection, bone marrow suppression, cutaneous and
noncutaneous malignancy, and metabolic complications (Click
2019). Consequently, complementary and alternative treatments
for CD have been sought. The previous version of this Cochrane
Review found only found one eligible small study with 11
participants (Butterworth 2008). There was insuGicient evidence to
make any conclusions about whether probiotics were eGective to
treat CD. This review will update the prior review with any new
studies that may have emerged over the past decade on the use of
probiotics for the induction of remission in CD.
O B J E C T I V E S
To assess the eGicacy and safety of probiotic supplementation for
the induction of remission in Chron's disease.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs)
Types of participants
All patients with active CD at the time of study entry, as defined
by a recognised CD activity index, endoscopy, histopathology, or
radiology.
Types of interventions
The intervention was probiotics, either alone or in combination
with other therapies, administered orally in any form (e.g. drink,
powder, capsule). The control was placebo, other non-probiotic
therapies, or no intervention.
Types of outcome measures
Primary outcomes
• Clinical remission, as defined by the primary studies
Secondary outcomes
• Disease improvement (clinical response, corticosteroid
withdrawal, endoscopic remission, histology scores,
biochemical markers of inflammation, quality-of-life scores)
• Escalation of therapy (addition of therapy, surgery)
• Adverse events (number of adverse events, withdrawal due to
adverse events)
Search methods for identification of studies
A comprehensive search for relevant RCTs was performed
independently of the search from the previous review. The search
strategy is outlined in Appendix 1.
Electronic searches
The following electronic databases were searched: MEDLINE (from
inception to 6 July 2020), Embase (from inception to 6 July 2020),
the Cochrane Central Register of Controlled Trials (CENTRAL), The
Cochrane Gut Review Group Specialised Trials Register, World
Probiotics for induction of remission in Crohn's disease (Review)
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Health Organization (WHO) International Clinical Trials Registry,
and ClinicalTrials.gov.
Searching other resources
Handsearches were performed of conference proceedings from the
Falk Symposium, Digestive Disease Week (DDW), American College
of Gastroenterology (ACG) Annual Scientific Meeting, Crohn's &
Colitis Congress (CCC), European Crohn's & Colitis Organisation
(ECCO) Congress, and the United European Gastroenterology
Week (UEGW). Additional studies were identified by checking
the references section of published trials and review articles on
probiotics for treatment of CD. Communication via email, formal
letter, or telephone was addressed to lead authors of relevant
ongoing or unpublished studies.
Data collection and analysis
This review was performed according to the methods outlined
in the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2017).
Selection of studies
Study selection was performed using Covidence. Two review
authors examined all citations and abstracts derived from the
electronic search strategy and independently selected trials
meeting the inclusion criteria. ANer the initial screen, full-text
articles of the selected trials were obtained for further scrutiny. Any
disagreements were resolved by discussion or by consulting a third
author where necessary.
Data extraction and management
Data extraction was carried out independently by two review
authors, using piloted forms. The data collected included
information on the study design, participants, intervention,
comparator, and outcomes. Discrepancies in data extraction were
discussed and, if necessary, a third review author was consulted.
Data were then entered into the review file by two authors.
Assessment of risk of bias in included studies
The review authors independently carried out a 'Risk of bias'
assessment of the included studies. The Cochrane 'Risk of bias' tool
(Higgins 2017) was used to assess the following domains.
• Random sequence generation
• Allocation concealment
• Blinding of participants and personnel
• Blinding of outcome assessment
• Incomplete outcome data
• Selective outcome reporting
• Other sources of bias
We considered subjective outcomes separately in our assessment
of blinding and incompleteness of data. Studies were judged to be
at high, low, or unclear risk of bias for each domain assessed. We
judged the risk of bias across studies as follows.
• Low risk of bias (plausible bias unlikely to seriously alter the
results) if all domains are at low risk of bias
• Unclear risk of bias (plausible bias that raises some doubt about
the results) if one or more domains are at unclear risk of bias
• High risk of bias (plausible bias that seriously weakens
confidence in the results) if one or more domains are at high risk
of bias
Measures of treatment e:ect
The treatment eGects of dichotomous outcomes were expressed as
risk ratios.
Unit of analysis issues
The unit of analysis was the participant. Studies involving multiple
trial arms would have been handled according to methods
proposed in Higgins 2017. Unit of analysis issues arising from
the measurement of outcomes at diGerent time points were
considered.
Dealing with missing data
We contacted study authors for missing data. Where possible,
intention-to-treat analysis was applied. Missing standard
deviations were calculated from other reported data (such as P
values, confidence intervals, and standard error) where possible.
However, missing data did not have to be imputed. In reporting
adverse events, we assumed the 'worst case' to avoid under-
reporting. For instance, we assumed that minor and serious
adverse events were related to the intervention.
Assessment of heterogeneity
The decision to pool the results of individual studies depended on
an assessment of clinical and methodological heterogeneity. If we
considered studies suGiciently homogeneous for data pooling, we
assessed statistical heterogeneity by visual inspection of the forest
plots, and using the Chi2 test with a significance level at P value
less than 0.1. We also used the I2 statistic, for which we based our
interpretations on those suggested by Higgins 2017:
• 0% to 40%: might not be important;
• 30% to 60%: may represent moderate heterogeneity;
• 50% to 90%; may represent substantial heterogeneity;
• 75% to 100%: considerable heterogeneity
Assessment of reporting biases
Various reporting biases were avoided by undertaking an extensive
literature search without restrictions on publication date or
language. Study protocols and trial registrations were used in
assessing studies for selective reporting. We did not assess
publication bias with a funnel plot due to there only being two
included studies.
Data synthesis
Data were analysed using Review Manager 5.4. For dichotomous
outcomes, risk ratios and 95% confidence intervals were derived
for each study. The results of included studies were combined for
each outcome, if appropriate. We used a random-eGects model for
pooled data and considered not pooling data if we encountered
considerable heterogeneity (I2 value of 75% or more) across
studies. However, data not amenable to pooling would have been
presented in a narrative summary.
We used the GRADE approach to assess the certainty of
evidence based on the primary outcome of clinical remission
Probiotics for induction of remission in Crohn's disease (Review)
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(Schünemann 2011). The four levels of evidence certainty were
"high", "moderate", "low", or "very low". "High certainty" suggests
that we are very confident that the true eGect lies close to that
of the estimate of the eGect. "Moderate certainty" suggests we
are moderately confident in the eGect estimate. "Low certainty"
suggests that our confidence in the eGect estimate is limited. "Very
low certainty" suggests that we have very little confidence in the
eGect estimate. The level of certainty was downgraded based on
risk of bias, imprecision, inconsistency, indirectness, or publication
bias. Where there was suGicient evidence, we prepared 'Summary
of findings' tables for our main comparisons. Two review authors
independently produced Summary of findings 1.
Subgroup analysis and investigation of heterogeneity
There were inadequate data to perform a subgroup analysis.
Sensitivity analysis
There were inadequate data to perform a sensitivity analysis.
R E S U L T S
Description of studies
There were 16 potentially relevant published studies and clinical
trials registrations identified for full-text review aNer title and
abstract screening (Figure 1). We excluded 14 studies. One study
included patients with active and quiescent CD (Yılmaz 2019). One
study did not diGerentiate between patients with CD and ulcerative
colitis (Ye 2017). Two studies used the wrong intervention: all
participants received probiotics in one study (Plein 1993), and in
the other study, corticosteroids were provided in the intervention
arm but not in the control arm (Su 2018). Another study did not
have adequate data and we were unable to obtain more data
from the trial authors (Day 2012). Four clinical trial registrations
had an unclear status that we were unable to confirm with
the authors (ACTRN12614000465651; NCT00367705; NCT00374374;
NCT01548014). Five clinical trial registrations were considered
duplicate entries.
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Figure 1.   PRISMA study flow diagram.
 
ANer full-text review, there were two studies that met the criteria
for inclusion (Schultz 2004; Steed 2010). This adds one new study
to the previous version of this review.
Schultz 2004 included 11 adult participants with active mild-
to-moderate CD (Crohn's Disease Activity Index (CDAI) score of
150 to 300). Participants were treated with a one-week course
of corticosteroids and antibiotics (ciprofloxacin 500 mg twice
daily and metronidazole 250 mg three times a day), followed by
Probiotics for induction of remission in Crohn's disease (Review)
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randomised assignment to Lactobacillus rhamnosus strain GG (two
billion colony-forming units per day) or corn starch placebo. Clinical
remission was defined as a CDAI score of less than 150 within the
six-month follow-up period. Sustained remission was defined as
remission at six months.
Steed 2010 included 35 adult participants with active CD (CDAI
score of 150 to 450), randomised to receive a synbiotic treatment
or placebo. The synbiotic treatment was a formulation of pro- and
prebiotics. This study used the combination of 2 x 1011 freeze-dried
Bifidobacterium longum and 6 g Synergy I (OraNi, Tienen, Belgium)
twice daily. Clinical remission was defined as a CDAI score of less
than 150 or a drop in CDAI score of more than 75 from baseline.
The two studies did not have evidence of statistical heterogeneity
(I2 = 0%), although there was substantial methodological
heterogeneity between them.
Risk of bias in included studies
Figure 2 outlines the 'Risk of bias' assessments for the included
studies. Schultz 2004 was a randomised double-blind trial,
although there were no details provided on random sequence
generation, allocation concealment, and blinding of participants
and outcome assessors. This led to an unclear risk of bias in
these domains. Steed 2010 provided details on random sequence
generation (a random numbers table was used by an independent
clinician otherwise not involved with the study) and blinding of
participants and outcome assessors. There was no information
in either study to suggest attrition or reporting bias; all outcome
data for all participants was reported, and there was appropriate
reporting of key outcomes specified in their methods, despite the
lack of a protocol for both studies.
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Schultz 2004 ? ? ? ? + + +
Steed 2010 + ? + + + + +
 
E:ects of interventions
See: Summary of findings 1 Probiotics compared to placebo for
induction of remission in Crohn's disease
Clinical remission
There was no statistically significant diGerence between probiotics
and placebo for the induction of remission in CD (risk ratio [RR] 1.06;
95% confidence interval [CI] 0.65 to 1.71; 2 studies, 46 participants)
(Figure 3). Due to the risk of bias and small sample size, the certainty
of this evidence was very low (Summary of findings 1). In Steed
2010, the mean CDAI scores dropped significantly in the synbiotic
group (219 ± 75 to 147 ± 74, P = 0.020) but did not change in the
placebo group (249 ± 79 to 233 ± 155, P = 0.810).
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Heterogeneity: Tau² = 0.00; Chi² = 0.57, df = 1 (P = 0.45); I² = 0%
Test for overall effect: Z = 0.23 (P = 0.82)
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Escalation of therapy
The data were unavailable to assess this outcome.
Adverse events
In Steed 2010, two participants discontinued synbiotic use due
to unreported side eGects (one participant) and intolerance (one
participant). There were no reported adverse eGects in the placebo
arm. In Schultz 2004, no adverse events were reported in the
11 participants who took part in the induction and maintenance
phases of the study. There was no diGerence in adverse events
between probiotics and placebo (RR 2.55; CI 0.11 to 58.60; 2 studies,
46 participants). The evidence is of very low certainty due to risk of
bias and imprecision.
D I S C U S S I O N
Probiotics have previously been shown to be helpful in
the treatment of ulcerative colitis and other gastrointestinal
disorders, which would support the hypothesis that microbiome
manipulation could benefit inflammatory bowel diseases.
However, despite the theoretical potential of probiotics for the
treatment of CD, the pooled analyses in this review did not find
a benefit of probiotics for induction of remission. If true, the
reason for the disparity of benefit from the use of probiotics
in the two types of inflammatory bowel diseases would need
clarification. One possible explanation may relate to the diGering
nature of inflammation between the two diseases: CD is generally
characterised by transmural inflammation with potential to form
strictures and fistulae, while ulcerative colitis is limited to
superficial epithelial inflammation. Another possibility may relate
to the choice of probiotics: the reviewed studies for CD only
included Lactobacillus rhamnosus strain GG and Bifidobacterium
longum. Other bacterial species or even multi-strain probiotics
could possibly instead be more eGective. For ulcerative colitis, a
meta-analysis of single-strain probiotics including Bifidobacterium
strains or Escherichia coli were not found to be eGective for inducing
remission (Shen 2014). On the other hand, a multi-strain probiotic
that also included Bifidobacterium strains was demonstrated to
be eGective for induction of remission. Moreover, this review's
findings are limited by the great paucity of data on the use of
probiotics for CD. This review included only two studies and 57
participants, leading to a high risk of type II error of not being
adequately powered to detect a significant diGerence. There was
substantial methodologic heterogeneity between the two studies
and the certainty of available evidence was graded as very low.
In this setting, the benefit — or lack thereof — of probiotics for
induction of remission in CD is still unknown and no conclusions
can be drawn at this time.
There has been very little research progress over the past decade.
This update to the original systematic review published in 2008
only adds one more study for inclusion. There are additionally
several dated clinical trials registrations that have not yet been
published (we could not reach the investigators for status updates).
Probiotics have been studied in a number of areas of inflammatory
bowel diseases, on which there are Cochrane Reviews pending
publication at the time of writing. However, it is possible that the
scientific community has already deemed probiotics as unsuitable
for CD and has therefore abandoned further study in this area.
This may nonetheless be a premature assessment, as further
investigation is clearly needed to conclude whether probiotics do
or do not help induce remission in CD.
A U T H O R S '   C O N C L U S I O N S
Implications for practice
The avaiable evidence was to uncertain to provide information on
the eGicacy or safety of probiotics for the induction of remission in
Crohn's disease.
Implications for research
This review highlights the need for good quality, adequately
powered randomised controlled trials to investigate the eGicacy
and safety of probiotics for the induction of remission in Crohn's
disease. Given that investigation in ulcerative colitis has found
some evidence for the eGicacy of probiotics, future research is
warranted.
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Characteristics of included studies [ordered by study ID]
 
Study characteristics
Methods Study design: randomised, double-blind, placebo-controlled trial
Schultz 2004 
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Setting: University of Regensburg (Regensburg, Germany)




Number randomised (n = 11): 5 (Group 1); 6 (Group 2)
Interventions Group 1: one week of corticosteroids and antibiotics (ciprofloxacin 500 mg bid, metronidazole 250 mg
tid), followed by 2 x 109 CFU/day of Lactobacillus rhamnosus strain GG (CAG Functional Foods, Omaha,
NE)
Group 2: one week of corticosteroids and antibiotics, followed by placebo
Outcomes Duration of follow-up: 24 weeks








Notes Funding source: partly funded by Deutsche Morbus Crohn und Colitis ulcerosa Vereinigung e.V. (DCCV)
Conflicts of interest: none declared
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)










Unclear risk There were no details on the methods of blinding and no response to email.
Blinding of outcome as-
sessment (detection bias)
All outcomes





Low risk Attrition rates appeared to be low, and balanced, and all attrition was report-
ed.
Schultz 2004  (Continued)
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Selective reporting (re-
porting bias)
Low risk The trial registration/protocol was not available, although the intended out-
comes specified in the methods were reported and these were as expected.





Methods Study design: randomised, double-blind, placebo-controlled trial
Setting: Ninewells Hospital (Dundee, United Kingdom)
Participants Inclusion: adults aged between 18 and 79 with CD (CDAI 150-450)
Exclusion: pregnancy, alterations to medications within last 3 months, antibiotic treatment within last
3 months, indeterminate colitis, UC, short bowel syndrome, use of commercially available prebiotic or
probiotic within the last 3 months
Age: mean 46.3 years (Group 1); 49.0 years (Group 2) (analysis set)
Sex: 13 male / 11 female (analysis set)
Number randomised (n = 35): Group 2 (19); Group 2 (16)
Interventions Group 1: 2 x 1011 freeze-dried Bifidobacterium longum and 6 g Synergy I (OraNi, Tienen, Belgium) bid
Group 2: placebo
Outcomes Duration of follow-up: 6 months
Primary outcome: mucosal tumour necrosis factor-alpha (TNF-α)
Secondary outcomes:
1. Remission (CDAI < 150 or drop in CDAI > 75 from baseline)





Notes Funding source: Government Chief Scientist Office, Scotland, United Kingdom
Conflicts of interest: none
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)




Unclear risk There were no details on allocation concealment and no response to email en-
quiry.
Steed 2010 
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Low risk "All study personnel and participants were blinded to treatment assignment"
and "(t)he appearance of the synbiotic and placebo were identical".
Blinding of outcome as-
sessment (detection bias)
All outcomes
Low risk "All study personnel and participants were blinded to treatment assignment"




Low risk Attrition was balanced across groups, relatively low and all reasons reported.
Selective reporting (re-
porting bias)
Low risk The intended outcomes specified in the methods were reported and these
were as expected.
Other bias Low risk The groups appeared to be balanced.
Steed 2010  (Continued)
bid: two times a day
CD: Crohn's disease
CDAI: Crohn's Disease Activity Index
CFU: colony-forming unit
CRP: C-reactive protein
IBD: inflammatory bowel disease
tid: three times a day
UC: ulcerative colitis
 
Characteristics of excluded studies [ordered by study ID]
 
Study Reason for exclusion
ACTRN12614000465651 Authors contacted on 30 May 2019, with no response
Day 2012 Clinical response and remission rates not reported according to treatment arm. Authors contacted
on 2 June 2019, with initial response but none thereafter
NCT00367705 Authors contacted on 30 May 2019, without response
NCT00374374 Authors contacted on 31 May 2019, without response
NCT01548014 Authors contacted on 15 June 2019, without response
Plein 1993 All patients received probiotics during the induction phase
Su 2018 Probiotic arm received corticosteroids, which the control arm did not receive
Ye 2017 Outcomes were not divided according to IBD type: CD and UC
Yılmaz 2019 Study criteria included patients with active and quiescent CD
CD: Crohn's disease
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D A T A   A N D   A N A L Y S E S
 
Comparison 1.   Probiotics versus placebo





Statistical method Effect size
1.1 Induction of remission 2 46 Risk Ratio (M-H, Random, 95% CI) 1.06 [0.65, 1.71]
1.2 Adverse events leading to withdraw-
al
2 46 Risk Ratio (M-H, Random, 95% CI) 2.55 [0.11, 58.60]
 
 






Heterogeneity: Tau² = 0.00; Chi² = 0.57, df = 1 (P = 0.45); I² = 0%
Test for overall effect: Z = 0.23 (P = 0.82)
























M-H, Random, 95% CI
0.96 [0.55 , 1.69]
1.35 [0.55 , 3.31]
1.06 [0.65 , 1.71]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favors placebo Favors probiotic
 
 







Test for overall effect: Z = 0.59 (P = 0.56)























M-H, Random, 95% CI
Not estimable
2.55 [0.11 , 58.60]
2.55 [0.11 , 58.60]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours [Probiotics] Favours [Placebo]
 
 
A P P E N D I C E S




3. (crossover$ or cross over$ or cross-over$).tw.
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8. (singl$ adj blind$).tw.
9. (double$ adj blind$).tw.




14. double blind procedure/
15. single blind procedure/
16. triple blind procedure/
17. randomized controlled trial/
18. Or/1-17
19. Exp Crohn disease/
20. Crohn*.mp.
21. IBD.mp.








30. (bifidus or bifidobacter*).tw.
31. exp Streptococcus thermophilus/
32. streptococc*.tw.
33. exp Lactococcus/
34. exp Bacillus subtilis/
35. exp Enterococcus/
36. exp Enterococcus faecium/ or Enterococcus faecalis/
37. exp Saccharomyces/
38. leuconostoc*.tw.
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39. pediococc*.tw.
40. bulgarian bacillus*.tw.
41. (beneficial adj3 bacter*).tw.
42. (Escherichia coli or "E. coli").tw.
43. Yeast.tw.
44. (fungus or fungi).tw.
45. (VSL# 3 or VSL 3).tw.
46. Or/24-45









8. (singl$ adj blind$).tw.
9. (double$ adj blind$).tw.
10. (tripl$ adj blind$).tw.
11. assign$.tw.
12. allocat$.tw.
13. randomized controlled trial/
14. or/1-13
15. Exp Crohn disease/
16. Crohn*.mp.
17. IBD.mp.
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26. (bifidus or bifidobacter*).tw.
27. exp Streptococcus thermophilus/
28. streptococc*.tw.
29. exp Lactococcus/
30. exp Bacillus subtilis/
31. exp Enterococcus/





37. (beneficial adj3 bacter*).tw.
38. (Escherichia coli or "E. coli").tw.
39. Yeast.tw.
40. (fungus or fungi).tw.
41. (VSL# 3 or VSL 3).tw.
42. Or/20-41
43. 14 and 19 and 42
Cochrane CENTRAL
#1 MeSH: [Crohn’s Disease] explode all trees
#2 Inflammatory bowel disease
#3 IBD
#4 #1 or #2 or #3
#5 MeSH descriptor: [Probiotics] explode all trees
#6 MeSH descriptor: [Synbiotics] explode all trees
#7 MeSH descriptor: [Lactobacillus] explode all trees
#8 Lactobacilli*
#9 Bacill*
#10 MeSH descriptor: [Bifidobacterium] explode all trees
#11 bifidus*
#12 bifidobacter*
#13 MeSH descriptor: [Streptococcus thermophilus] explode all trees
#14 streptococc*
#15 MeSH descriptor: [Lactococcus] explode all trees
#16 MeSH descriptor: [Bacillus subtilis] explode all trees
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#17 MeSH descriptor: [Enterococcus] explode all trees
#18 MeSH descriptor: [Enterococcus faecium] explode all trees
#19 MeSH descriptor: [Enterococcus faecalis] explode all trees




#24 beneficial adj3 bacter*
#25 Escherichia coli or "E. coli"
#26 Yeast
#27 fungus or fungi
#28 VSL# 3 or VSL 3
#29 #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24 or
#25 or #26 or #27 or #28
#30 #4 and #29
Cochrane CENTRAL
#1 MeSH: [Crohn’s Disease] explode all trees
#2 Inflammatory bowel disease
#3 IBD
#4 #1 or #2 or #3
#5 MeSH descriptor: [Probiotics] explode all trees
#6 MeSH descriptor: [Synbiotics] explode all trees
#7 MeSH descriptor: [Lactobacillus] explode all trees
#8 Lactobacilli*
#9 Bacill*
#10 MeSH descriptor: [Bifidobacterium] explode all trees
#11 bifidus*
#12 bifidobacter*
#13 MeSH descriptor: [Streptococcus thermophilus] explode all trees
#14 streptococc*
#15 MeSH descriptor: [Lactococcus] explode all trees
#16 MeSH descriptor: [Bacillus subtilis] explode all trees
#17 MeSH descriptor: [Enterococcus] explode all trees
#18 MeSH descriptor: [Enterococcus faecium] explode all trees
#19 MeSH descriptor: [Enterococcus faecalis] explode all trees
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#24 beneficial adj3 bacter*
#25 Escherichia coli or "E. coli"
#26 Yeast
#27 fungus or fungi
#28 VSL# 3 or VSL 3
#29 #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24 or
#25 or #26 or #27 or #28
#30 #4 and #29
Clinicaltrials.gov
1. Probiotics and Crohn’s Disease (19)
2. Probiotics and Inflammatory bowel disease (43)
WHO trials registry
1. Probiotics and Crohn’s Disease (14)
2. Probiotics and Inflammatory bowel disease (14)
IBD specialized register
1. Probiotics and Crohn’s Disease (3)
2. Probiotics and Inflammatory bowel disease (0)
W H A T ' S   N E W
 
Date Event Description
6 July 2020 New citation required but conclusions
have not changed
One study (Steed 2010) was added. Conclusions are unchanged.
6 July 2020 New search has been performed New search performed on 6 July 2020. Risk of bias and GRADE
assessments were performed. Summary of Findings table was
added.
 
H I S T O R Y
Protocol first published: Issue 3, 2007
Review first published: Issue 3, 2008
 
Date Event Description
12 May 2008 Amended Converted to new review format
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• No sources of support supplied
D I F F E R E N C E S   B E T W E E N   P R O T O C O L   A N D   R E V I E W
There are several diGerences in the methods between the current update and the original review, as follows.
• Manufacturers of probiotics were not contacted for data on any unpublished trials, as these were felt to have been adequately captured
in the clinical trials registries.
• A PRISMA flow diagram was added.
• 'Risk of bias' assessments were included.
• The certainty of data was assessed using GRADE methodology.
• A 'Summary of findings' table was added
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I N D E X   T E R M S
Medical Subject Headings (MeSH)
Crohn Disease  [*therapy];  Probiotics  [*therapeutic use];  Randomized Controlled Trials as Topic;  Remission Induction
MeSH check words
Humans
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